ADC Fall An update on biomarkers in AD and non-ad dementias
|
|
- Imogen Preston
- 5 years ago
- Views:
Transcription
1 ADC Fall 2010 An update on biomarkers in AD and non-ad dementias Thomas J. Montine, MD, PhD Alvord Chair of Neuropathology Professor of Pathology and Neurological Surgery University of Washington Adjunct Professor of Neurology Oregon Health & Science University
2 Stages of s to be met by biomarkers and molecular neuroimaging Laboratory Determine degree and character of functional impairment Normal Mild Impairment Moderate to Severe Impair. Classify disease type and burden of lesions None Stage No Latency Prodrome Dementia
3 Stages of s to be met by biomarkers and molecular neuroimaging Laboratory Determine degree and character of functional impairment Normal Mild Impairment Moderate to Severe Impair. Classify disease type and burden of lesions None Stage No Latency Prodrome Dementia
4 Stages of s to be met by biomarkers and molecular neuroimaging Laboratory Determine degree and character of functional impairment Normal Mild Impairment Moderate to Severe Impair. Classify disease type and burden of lesions None Stage No Latency Prodrome Dementia
5 Stages of s to be met by biomarkers and molecular neuroimaging Neuropath Imaging Biomarkers Stage Determine degree and character of functional impairment Normal Mild Impairment AD, LBD, and µvbi Moderate to Severe Impair. None No Identify diseasespecific latency Latency Prodrome Dementia Quantify disease-specific progression Quantify pharmacologic activity of experimental therapeutics
6 Stages of s to be met by biomarkers and molecular neuroimaging Neuropath Imaging Biomarkers Stage Determine degree and character of functional impairment Normal Mild Impairment AD, LBD, and µvbi Moderate to Severe Impair. None No Latency Prodrome Dementia Identify disease-specific latency and prodrome Quantify disease progression Quantify pharmacologic activity of experimental therapeutics
7 Quality of evidence Compartment Level 1 Initial Associations Association with expert diagnosis Level 2 Confirmation Replication in independent sample that includes multiple related diseases Level 3 Validation Further replication in independent samples from multiple sites Level 4 Research Standardization of assay and use as disease surrogate in clinical research Level 5 Primary Care Adopted as part of standard work-up in primary care setting
8 Quality of evidence Compartment
9 Quality of evidence Compartment CSF continues to be the site to yield reproducible results for diseases that cause cognitive impairment and dementia.
10 CSF biomarkers for AD CSF biomarkers of drug action CSF biomarkers for cognitive impairment in PD Evidence Latency Prodrome Dementia Level 1 Level 2 Level 3 Level 4 Level 5 Several F 2 -IsoPs tau-p231 Aβ 42, T-tau, tau-p181 None Many candidates F 2 -IsoPs, BACE1 tau-231 Aβ 42 and T-tau tau-p181 Many candidates A few MAPs tau-p231 F 2 -IsoPs Aβ 42, T-tau, tau-p181 None None None
11 CSF biomarkers for AD CSF biomarkers of drug action CSF biomarkers for cognitive impairment in PD Evidence Latency Prodrome Dementia Level 1 Level 2 Level 3 Level 4 Level 5 Several F 2 -IsoPs tau-p231 Aβ 42, T-tau, tau-p181 None Many candidates F 2 -IsoPs, BACE1 tau-231 Aβ 42 and T-tau tau-p181 Many candidates A few MAPs tau-p231 F 2 -IsoPs Aβ 42, T-tau, tau-p181 None None None
12 CSF biomarkers for AD CSF biomarkers of drug action CSF biomarkers for cognitive impairment in PD
13 CSF biomarkers for AD CSF biomarkers of drug action CSF biomarkers for cognitive impairment in PD
14 Summary Neuropath Imaging Biomarkers Stage Determine degree and character of functional impairment Normal Mild Impairment AD, LBD, and µvbi Moderate to Severe Impair. None No Latency Prodrome Dementia Identify disease-specific latency and prodrome Quantify disease progression Quantify pharmacologic activity of experimental therapeutics
15 Summary CSF Aβ42 and tau species for AD CSF Aβ42 for PD Neuropath Imaging Biomarkers Stage Determine degree and character of functional impairment Normal Mild Impairment AD, LBD, and µvbi Moderate to Severe Impair. None No Latency Prodrome Dementia Identify disease-specific latency and prodrome Quantify disease progression Quantify pharmacologic activity of experimental therapeutics
16 Summary CSF Aβ42 and tau species for AD CSF Aβ42 for PD Neuropath Imaging Biomarkers Stage Determine degree and character of functional impairment Normal Mild Impairment? CSF tau and others AD, LBD, and µvbi Moderate to Severe Impair. None No Latency Prodrome Dementia Identify disease-specific latency and prodrome Quantify disease progression Quantify pharmacologic activity of experimental therapeutics
17 Summary CSF Aβ42 and tau species for AD CSF Aβ42 for PD Neuropath Imaging Biomarkers Stage Determine degree and character of functional impairment Normal Mild Impairment? CSF tau and others AD, LBD, and µvbi Moderate to Severe Impair. None No CSF Aβ42 production for GSIs CSF F 2 -IsoPs for anti-oxidants Latency Prodrome Dementia Identify disease-specific latency and prodrome Quantify disease progression Quantify pharmacologic activity of experimental therapeutics
18 Future Directions Patient Evaluation Medical history and genetics to quantify risk examination and neuropsych testing Laboratory: Ensemble of imaging and biomarker data Aid in diagnosis Establish disease stage Quantify progression or response to therapy Research needs Reproducible peripheral biomarkers Focus on latent and prodromal stages Demonstrate pharmacologic action prior to therapeutic trial
19 Thanks to Patients and their families Members of UW ADRC Alvord Endowment NIH for support
25 th Annual Southern California Alzheimer s Disease Research Conference
25 th Annual Southern California Alzheimer s Disease Research Conference New Guidelines and Importance of Brain Donation Thomas J. Montine, MD, PhD Alvord Professor & Chair Department of Pathology University
More informationRe: Request for Information: Updating the Alzheimer s Disease-Related Dementias Research Priorities
Public Policy Division 202.393.7737 p 1212 New York Ave NW 866.865.0270 f Suite 800 www.alz.org Washington, DC 20005 Roderick Corriveau, Ph.D. Program Director National Institute of Neurological Disorders
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationHuman Neurology 3-Plex A
Human Neurology 3-Plex A SUMMARY AND EXPLANATION OF THE TEST The Human N3PA assay is a digital immunoassay for the quantitative determination of total Tau, Aβ42, and Aβ40 in human plasma and CSF. Determination
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationTUESDAY, MARCH 26, 2019 WEDNESDAY, MARCH 27, 2019
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 26, 2019
More informationRegulatory Challenges across Dementia Subtypes European View
Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions
More information3/7/2017. Alzheimer s and Dementia Research: An Advanced Discussion. Alzheimer s and Dementia Research: An Advanced Discussion
Alzheimer s and Dementia Research: An Advanced Discussion Brad Boeve, MD Department of Neurology Mayo Clinic Alzheimer s and Dementia Research: An Advanced Discussion Theoretical Constructs in Aging/Dementia
More informationAlzheimer s Disease Neuroimaging Initiative
Alzheimer s Disease Neuroimaging Initiative Steering Committee Meeting April 18, 2016 Neuropathology Core John C. Morris, MD Nigel J. Cairns, PhD, FRCPath Erin Franklin, MS Table 1. Participants Autopsied
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationSleep and Circadian Rhythms in Neurodegenerative Disorders
Sleep and Circadian Rhythms in Neurodegenerative Disorders Erik S. Musiek, MD, PhD Department of Neurology Washington University in St. Louis U13 Bench to Bedside Sleep Conference 2015 Disclosures Funding:
More informationEuropean Prevention of Alzheimer s Dementia (EPAD)
European Prevention of Alzheimer s Dementia (EPAD) Ron Marcus, MD ISCTM Adaptive Design Workshop February 20, 2018 1 EPAD Goal The European Prevention of Alzheimer's Dementia (EPAD) project aims to develop
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a postprint version which may differ from the publisher's version. For additional information about this
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationAlzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS)
Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS) AN OVERVIEW (with material provided by Ben Handen & Nicole Schupf) https://www.nia.nih.gov/research/abc-ds Alzheimer s Biomarkers Consortium
More informationTUESDAY, MARCH 28, 2017 WEDNESDAY, MARCH 29, 2017 WELCOME RECEPTION (VIENNA CITY HALL)
KEY: PRE CONFERENCE SYMPOSIUM SPONSORED SYMPOSIUM SYMPOSIUM PLENARY LECTURE FORUM OTHER EVENT *PRE-REGISTRATION IS REQUIRED FOR THE INFORMAL NETWORKING WITH PROFESSOR LUNCH SESSION TUESDAY, MARCH 28, 2017
More informationIan McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University
Ian McKeith MD, F Med Sci, Professor of Old Age Psychiatry, Newcastle University Design of trials in DLB and PDD What has been learnt from previous trials in these indications and other dementias? Overview
More informationTheme Topics Subtopics. Basic and Translational Science. Development of New Models and Analysis Methods
Basic and Translational Science Development of New Models and Analysis Methods α-synuclein Amyloid/Abeta Behavioral models Inflammation Novel assays and technologies Screening studies/platforms Seeding
More informationAlzheimer s Disease Centers meeting San Diego, CA October 14, NIA-Division of Neurosciences update"
Alzheimer s Disease Centers meeting San Diego, CA October 14, 2017 NIA-Division of Neurosciences update" Eliezer Masliah, M.D. Director, Division of Neuroscience, National Institute on Aging, NIH AD grants
More informationThe Aging Brain The Aging Brain
The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu
More informationWashington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease
Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement
More informationHow to Diagnose Early (Prodromal) Lewy Body Dementia. Ian McKeith MD, FRCPsych, F Med Sci.
How to Diagnose Early (Prodromal) Lewy Body Dementia Ian McKeith MD, FRCPsych, F Med Sci. Parkinson s Disease Lewy Body Disease Time PD Dementia Lewy Body Dementias Dementia with Lewy Bodies (DLB) Diagnostic
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationRoche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment
Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationNACC News. ADC Directors Meeting Atlanta, GA 20 Oct 2018
NACC News ADC Directors Meeting Atlanta, GA 20 Oct 2018 FOA NACC New Investigator Awards (full instructions on NACC Website) November 19, 2018 Letter of Intent (optional) January 21, 2019 Application due
More informationTau Mechanism in Dementia
ADC Directors Meeting Saturday, April 12, 2008 Sheraton V Tau Mechanism in Dementia Lennart Mucke, M.D. Director, Gladstone Institute of Neurological Disease Joseph B. Martin Distinguished Professor Department
More informationNIH Public Access Author Manuscript Neuromolecular Med. Author manuscript; available in PMC 2012 March 1.
NIH Public Access Author Manuscript Published in final edited form as: Neuromolecular Med. 2011 March ; 13(1): 37 43. doi:10.1007/s12017-010-8126-6. Increased Cerebrospinal Fluid F 2 -Isoprostanes are
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationDementia and Healthy Ageing : is the pathology any different?
Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association
More informationFINAL AGENDA Administrators Meeting
Administrators informal social hour (Food and drink on your own) 6 8pm Thursday, April 19 Hilton Checkers Los Angeles 535 S Grand Ave 90071 FINAL AGENDA Administrators Meeting Friday, April 20, 2018 1
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More informationDisclosure Statement
Recommendations on MCI from the Third and Fourth Canadian Consensus Conferences on Diagnosis and Therapy of Dementia/ Quatrieme Conférence Canadienne Consensuelle sur la Démence 2012. Dr. Howard Chertkow
More informationDelirium, Apo-E status, and AD CSF biomarkers
Delirium, Apo-E status, and AD CSF biomarkers Zhongcong Xie, M.D., Ph.D. Geriatric Anesthesia Research Unit Department of Anesthesia, Critical Care and Pain Medicine Massachusetts General Hospital Harvard
More informationPart 2: Early detection, assessment and treatment in relation to the new guidelines. Christopher Patterson McMaster University
Part 2: Early detection, assessment and treatment in relation to the new guidelines Christopher Patterson McMaster University C. Patterson MD, FRCPC Division of Geriatric Medicine, McMaster University
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationDepression: An Important Risk Factor for Cognitive Decline
Depression: An Important Risk Factor for Cognitive Decline No conflicts of interest Sarah K. Tighe, M.D. Assistant Professor University of Iowa Carver College of Medicine Department of Psychiatry Institute
More informationAIDS 2011, 3, 2011 RW
Treating CNS HIV Infection and Disease Why, How and When? Richard W. Price, M.D. Department of Neurology, UCSF/SFGH Preface: Reasons for Renewed Interest in Treatment of CNS HIV Continued CNS infection/disease
More informationADC Directors Meeting
ADC Directors Meeting (Grand Ballroom, The Roosevelt Hotel New York City, NY) 8:00 8:30 am Breakfast buffet 8:30 8:35 am Welcome: Jeffrey Kaye, MD, ADC Executive Committee Chair 8:35 9:00 am NIA Update:
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationRuolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce
Ruolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce ALESSANDRO MARTORANA UOC NEUROLOGIA-CENTRO ALZHEIMER POLICLINICO TOR VERGATA-UNIVERSITÀ DI ROMA TOR VERGATA
More informationNACC Minimum Data Set (MDS) Public Data Element Dictionary
Department of Epidemiology, School of Public Health and Community Medicine, University of Washington 4311 11 th Avenue NE #300 Seattle, WA 98105 phone: (206) 543-8637; fax: (206) 616-5927 e-mail: naccmail@u.washington.edu
More informationDiagnosis before NIA AA The impact of FDG PET in. Diagnosis after NIA AA Neuropathology and PET image 2015/10/16
The impact of FDG PET in degenerative dementia diagnosis Jung Lung, Hsu MD, Ph.D (Utrecht) Section of dementia and cognitive impairment Department of Neurology Chang Gung Memorial Hospital, Linkou, Taipei
More informationDementia: A Comprehensive Update Neuroimaging, CSF, and genetic biomarkers in dementia
Dementia: A Comprehensive Update 2016 Neuroimaging, CSF, and genetic biomarkers in dementia Bradford C. Dickerson, M.D. Associate Professor of Neurology, Harvard Medical School Departments of Neurology
More informationSeptember 30, Eric BASTINGS, MD. Acting Director Division of Neurology Products (DNP) Center for Drug Evaluation and Research (CDER)
ISCTM Autumn Conference Options and methods to improve cognitive assessment in clinical trials of AD and its precursors September 30, 2013 Eric BASTINGS, MD Acting Director Division of Neurology Products
More informationChange the size of any window by dragging the lower left corner. Use controls
Early Detection of Parkinson s s Disease Change the size of any window by dragging the lower left corner. Use controls in top right corner to close or maximize each window Use text box at bottom left to
More informationPlasma Phospholipids Identify Antecedent Memory Impairment in Older Adults. Madeline Haff, Bikem Sonmezler, & Rosie Chu
Plasma Phospholipids Identify Antecedent Memory Impairment in Older Adults Madeline Haff, Bikem Sonmezler, & Rosie Chu So what exactly is Alzheimer s Disease? A progressive form of dementia that causes
More informationStatins and Cognition A Focus on Mechanisms
Statins and Cognition A Focus on Mechanisms Note: Deleted copyrighted graphs/tables are described In red text and source references are provided Disclosures: SPARCL Steering Committee and past consultant
More informationAlzheimer s disease. The future of clinical trials: big problem, Big Data, big solution?
Alzheimer s disease The future of clinical trials: big problem, Big Data, big solution? The Problem More than 36m people with dementia Consumes 1% global GDP Serial trials failure Targets for therapy Nothing
More informationAlzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms. l The diagnosis of AD l Neuropsychiatric symptoms l Place of the ICT
Alzheimer's Disease An update on diagnostic criteria & Neuropsychiatric symptoms State of the art lecture March 4-2012 Philippe H Robert, Philippe Nice - France Robert The diagnosis of AD Neuropsychiatric
More informationEngineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos, Susan Resnik, Sterling Johnson, and Pierre Jedynak Longitudinal
More informationForm D1: Clinician Diagnosis
Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.
More informationOutline of Lecture 2/13/2018
Allan I. Pack, M.B.Ch.B., Ph.D., FRCP John Miclot Professor of Medicine Director, Center for sleep and Circadian Neurobiology University of Pennsylvania Perelman School of Medicine Philadelphia, Pennsylvania
More informationTammie Benzinger, MD, PhD
Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,
More informationEUROPEAN ADNI/PharmaCOG Papers in progress
EUROPEAN ADNI/PharmaCOG Papers in progress Journal Title 1st author *equally contributing authors Last author Status PLOS Medicine Development and validation of CSF cut-offs to predict progression in mild
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationUW Medicine Neuropathology
Neuropathology in Patient Care Surgical Neuropathology is that subspecialty of pathology that provides diagnoses on biopsies from the brain, spinal cord, skeletal muscle, peripheral nerve, and eye. In
More informationUsing Biomarkers to Increase the Efficiency of Early Stage Drug Development
Using Biomarkers to Increase the Efficiency of Early Stage Drug Development Personal consulting compensation received from Cytokinetics, Biogen, MT Pharma, Lilly, Karyopharm, Denali Goals of Talk Describe
More informationMolecular Imaging Heterogeneity of Clinically Defined AD
Molecular Imaging Heterogeneity of Clinically Defined AD Gil Rabinovici, M.D. Edward Fein & Pearl Landrith Endowed Professor UCSF Memory & Aging Center 2017 Spring ADC Meeting Boston, MA April 22, 2017
More informationThe Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing
The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2012 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader October 2011 The Australian Imaging Biomarkers
More informationMultiple choice questions: ANSWERS
Multiple choice questions: ANSWERS Chapter 1. Redefining Parkinson s disease 1. Common non-motor features that precede the motor findings in Parkinson s disease (PD) include all of the following except?
More informationDementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
More informationChronic Effects of Neurotrauma Consortium (CENC)
Chronic Effects of Neurotrauma Consortium (CENC) 2013-2019 David X. Cifu, MD Senior TBI Specialist, U.S. Department of Veterans Affairs Associate Dean for Innovation and System Integrations, Virginia Commonwealth
More informationImplementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative
Implementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative Leslie M Shaw Perelman School of Medicine, University of Pennsylvania
More informationADNI Biomarker Core. WWADNI meeting, Boston, MA, July 12, 2013
ADNI Biomarker Core Leslie M Shaw and John Q Trojanowski Department of Pathology & Laboratory Medicine Perelman School of Medicine University of Pennsylvania WWADNI meeting, Boston, MA, July 12, 2013 ADNI
More informationarxiv: v1 [stat.ml] 21 Sep 2017
Yet Another ADNI Machine Learning Paper? Paving The Way Towards Fully-reproducible Research on Classification of Alzheimer s Disease Jorge Samper-González 1,2, Ninon Burgos 1,2, Sabrina Fontanella 1,2,
More informationIndiana University School of Medicine, Indianapolis, IN USA 1
GWAS and Candidate Studies of MRI and Amyloid PET Phenotypes for Alzheimer's Disease Andrew J. Saykin Depts. of Radiology & Imaging Sciences and Medical & Molecular Genetics, Neurology & Psychiatry; Indiana
More informationNew Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International Conference
Media Contacts: David Patti JFK Communications dpatti@jfkhealth.com (609) 241-7365 New Research on Neuraceq TM (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer s Association International
More informationWhite matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration
White matter hyperintensities correlate with neuropsychiatric manifestations of Alzheimer s disease and frontotemporal lobar degeneration Annual Scientific Meeting Canadian Geriatric Society Philippe Desmarais,
More information! slow, progressive, permanent loss of neurologic function.
UBC ! slow, progressive, permanent loss of neurologic function.! cause unknown.! sporadic, familial or inherited.! degeneration of specific brain region! clinical syndrome.! pathology: abnormal accumulation
More informationHIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body
HIV 101: Overview of the Physiologic Impact of HIV and Its Diagnosis Part 2: Immunologic Impact of HIV and its Effects on the Body Melissa Badowski, PharmD, BCPS, AAHIVP Clinical Assistant Professor University
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationLearnings from Parkinson s disease: Critical role of Biomarkers in successful drug development
Learnings from Parkinson s disease: Critical role of Biomarkers in successful drug development Ken Marek Coalition Against Major Diseases and FDA 2014 Annual Scientific Workshop Oct 2014 Disclosure Co-founder
More informationNon-therapeutic and investigational uses of non-invasive brain stimulation
Non-therapeutic and investigational uses of non-invasive brain stimulation Robert Chen, MA, MBBChir, MSc, FRCPC Catherine Manson Chair in Movement Disorders Professor of Medicine (Neurology), University
More informationAssessment at the bedside or in the clinic using the history, examination and laboratory tests to distinguish between different types of dementia
Assessment at the bedside or in the clinic using the history, examination and laboratory tests to distinguish between different types of dementia AP Passmore Content Common dementia syndromes (older people)
More information8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research
The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event
More informationParkinson e decadimento cognitivo. Stelvio Sestini
Parkinson e decadimento cognitivo Stelvio Sestini Patients with PD can develop a spectrum of cognitive symptoms Heterogeneity of cognitive deficits The cognitive symptoms can evolve to dementia (Mov Disorder
More informationType 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky
Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationThe Role of Sphingolipids in Alzheimer s Disease, Parkinson s Disease and Lewy Body Dementia: A Common Pathway?
The Role of Sphingolipids in Alzheimer s Disease, Parkinson s Disease and Lewy Body Dementia: A Common Pathway? Michelle M. Mielke, PhD Professor of Epidemiology and Neurology Center for Healthy Brain
More informationMary Sano, PhD Mount Sinai School of Medicine James J Peters Veterans Affairs Hospital June 15, 2013
Preventing and Treating Alzheimer's Disease: Recruiting Patients for Clinical Trials Mary Sano, PhD Mount Sinai School of Medicine James J Peters Veterans Affairs Hospital June 15, 2013 Goals and Learning
More informationBioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018
Press release BioArctic announces detailed results of the BAN2401 Phase 2b study in early Alzheimer s disease presented at AAIC 2018 Stockholm, Sweden, July 25, 2018 BioArctic AB (publ) (Nasdaq Stockholm:
More informationComorbidities of Migraine
Comorbidities of Migraine Richard B. Lipton, MD Edwin S Lowe Professor and Vice Chair of Neurology Director, Montefiore Headache Center Albert Einstein College of Medicine Overview What is comorbidity?
More informationThe Marmoset Monkey as Model for Neurological Disorders
The Marmoset Monkey as Model for Neurological Disorders Jan Langermans and Ingrid Philippens From Laboratory to Clinic Disease models neuroscience: Parkinson, Sleep, Stress, Alzheimer, MS MS Models: rhmog
More informationThe importance of cognitive ageing for understanding dementia
The importance of cognitive ageing for understanding dementia Archana Singh-Manoux, PhD 1,2,3 Mika Kivimäki, PhD 2 * Corresponding author & address: 1 Centre for Research in Epidemiology & Population Health,
More informationPositioning. > MEMENTO is a large observational study enrolling patients at an. Data first availability for project analyses
: determinants and Evolution of AlzheiMer s disease and related disorders ITMO Santé publique OVERVIEW AT A GLANCE Bordeaux Geneviève Chêne, MD, PhD Professor of Biostatistics and Public Health, Bordeaux
More informationAlzheimer s Disease Update: From Treatment to Prevention
Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science
More informationINDUSTRY PERSPECTIVE ON DRUG DEVELOPMENT FOR TYPE 1 SMA
INDUSTRY PERSPECTIVE ON DRUG DEVELOPMENT FOR TYPE 1 SMA Kathie M. Bishop, PhD Disclosures: Currently, CSO of Tioga Pharmaceuticals, no activities in SMA; 2009-2015, full-time employee of Ionis Pharmaceuticals,
More informationFlorbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps
Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps The Harvard community has made this article openly available.
More informationDr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen. Dr. Michael Plopper. Dr. Guerry Peavy
1 Anne State 2 3 Dr. Michael Lobatz Dr. Michael Jackson Dr. James Brewer Dr. Paul Aisen Dr. Michael Plopper Dr. Guerry Peavy 4 Michael Lobatz, MD Medical Director, Neurosciences Medical Director, Rehabilitation
More informationGoal. To enhance the clinical, research, and education missions by further integrating patient care and research
Goal To enhance the clinical, research, and education missions by further integrating patient care and research Objectives & Strategies Establish & strengthen research activities in comparative effectiveness,
More informationNational Plan to Address Alzheimer s Disease What s Next?
National Plan to Address Alzheimer s Disease What s Next? Ronald C. Petersen, Ph.D., M.D. Mayo Clinic Rochester, MN Chair, Advisory Council on Research, Care and Services National Alzheimer s Project Act
More informationPiramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and Molecular Imaging 2017 Annual Meeting
FOR IMMEDIATE RELEASE Media Contacts: Nicole Fletcher Piramal Imaging nicole.fletcher@piramal.com (857) 202-1122 Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and
More informationFlicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease
Flicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease Mojtaba Golzan (Research Fellow-Alzheimer s Australia) Department of Clinical Medicine, Macquarie University Ms. Dana Georgevsky
More informationOpportunities in Pain Research with the NIH HEAL Initiative
Opportunities in Pain Research with the NIH HEAL Initiative Clinton Wright, M.D. Director, Division of Clinical Research National Institute of Neurological Disorders and Stroke, NIH September 20, 2018
More information